Undisclosed, Large Monkeypox Vaccine Order Announced

Denmark-based Bavarian Nordic A/S announced today the signing of a supply contract with an undisclosed country for the Company's smallpox vaccine with the aim to ensure sufficient supply to meet the country's requirements for vaccinating individuals at risk for monkeypox in the short to medium term.

The Modified Vaccinia Ankara (MVA-BN) vaccine is marketed as IMVANEX® in Europe, JYNNEOS® in the USA, and IMVAMUNE® in Canada is a non-replicating monkeypox/smallpox vaccine developed in collaboration with the U.S. government.

The vaccine is approved against monkeypox by the U.S. FDA and Health Canada.

Paul Chaplin, President and CEO of Bavarian Nordic, said in a related press statement issued on May 25, 2022, "The current monkeypox outbreak, which is now affecting countries globally, calls for a swift and coordinated response from health authorities, and we are pleased to assist another country with a supply of vaccines to fulfill a growing demand."

"Building on our vast experience and relations with governments in the procurement of vaccines for their national preparedness, we have rapidly adapted to this unprecedented situation and are working closely with other governments to make vaccines available as fast as possible to mitigate the situation."

While the terms of the agreement remain undisclosed, the order will positively impact the Company's financial guidance for 2022.

As a consequence of this order and improved exchange USD/DKK rates, Bavarian Nordic raises its expectations for the financial result for 2022, with revenue now expected to be between DKK 1,300 and 1,500 million (previously between DKK 1,100 and 1,400 million).

Additionally, Bavarian Nordic is currently in dialogue with several other governments concerning the supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer-term collaboration to build stockpiles for future preparedness.

Breaking news regarding the global monkeypox outbreak is posted at Vax-Before-Travel.

Note: This press release was manually curated for mobile readership.